An interventional study of Lugol - in Basedow Disease, sponsored by University of Padova. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-20.
Sponsored by University of Padova · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Graves Disease with a site in Italy — 5 open to participants now, 9 under way, 1 of them phase 3. Graves Disease · Italy.
Among the 14 studies in Graves Disease with a site in Italy, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 4 with no phase, and was the 5th registered.
162 studies on the registry are indexed under Graves Disease; 52 are open to participants now.
Browse Graves Disease studies →5 of the 14 studies in Graves Disease with a site in Italy are open now. Recruiting first, the newest first:
argenx · Sites in Italy, Belgium, Bulgaria and 11 more countries
Ages 18+
Immunovant Sciences GmbH · Sites in Italy, United States, Australia and 15 more countries
Ages 18–75
Immunovant Sciences GmbH · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–75
IRCCS Ospedale San Raffaele · Sites in Italy
Ages 2–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 38 Graves Disease studies recruiting now, 17 (45%) set no upper age limit and 19 (50%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 1
First in 2014; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 60 across the 11 interventional studies, 100 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
University of Padova is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
University of Padova has 1 study filed under Graves Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Graves Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06984627SanofiA Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | 2027-02-11 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Graves Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preoperative preparation of patient with Basedow's disease is crucial to avoid severe thyrotoxicosis resulting from leakage of thyroid hormone into the circulation at the time of surgery. Moreover, hyperthyroidism-related hypervascularization and tissue fragility caused by Basedow's disease thyroiditis may cause intraoperative bleeding that can reduce the visualization and preservation of parathyroid glands and laryngeal nerves with subsequent higher risk of related morbidity including neck hematoma, hypoparathyroidism and vocal cords paresis. Although some endocrine surgeons administer before surgery Lugol solution to decrease thyroid gland vascularity in Basedow's disease, there is still not an agreement on its effectiveness.
The aims of the present trial are to evaluate the impact of pre-operative short-term Lugol solution treatment (7 days) on surgical outcomes through modification of thyroid vascularity and surgical related morbidity, in patients with Basedow's disease.
The study will investigate the effects of Lugol solution treatment before surgery on thyroid vascularity and tissue fragility in patients with Basedow's disease, and if these changes are associated or not with different surgical outcomes.
Hyperthyroidism is associated with hemodynamic changes, decreasing peripheral resistance that are related to both direct cardio-stimulatory effects of thyroid hormone. Preoperative preparation of the patient is crucial to avoid intra-operative or postoperative thyroid storms and to decrease the vascularity of the gland.
Inorganic iodide (Lugol solution) decreases the synthesis of thyroid hormone and release of hormone from the thyroid in the short term. Iodine also seems to reduce thyroid cellularity and vascularity and therefore is used in the preparation of patients for thyroidectomy. This effect transiently blocks thyroid hormone generation, with thyroid hormone synthesis recovering in few days.
On this matter doppler techniques seem to be the best method to evaluate blood flow in the thyroid gland.
Thyroid vascularity in Basedow's disease patients can be evaluated by monitoring CD-34 and CD-31 expression using immunohistochemistry. The vascular density of different tissues has been assessed by counting vessels labeled using immunohistochemistry with antibodies against different endothelial markers on paraffin-embedded sections. Antibodies that are most commonly used are directed against the endothelial antigens factor eight-related antigen, CD-31 (platelet endothelial cell adhesion molecule), CD-34. CD-34 is the most sensitive and specific marker currently available for the detection of angiogenesis. The use of these markers reflects total vascular density.
Moreover some authors showed that iodide inhibits vascular endothelial growth factor (VEGF) expression in cultured human thyroid follicles, and, consequently, they suggest that pro-angiogenic and anti-angiogenic factors may at least partly account for the iodide-induced decrease in thyroid blood flow. Cross-talk between angiogenesis and inflammation has also been reported. T cells can deliver VEGF to inflammatory sites and VEGF can augment pro-inflammatory T cell differentiation and promote angiogenesis.
So the detection of VEGF could be useful in the demonstration of Lugol effect on pretreated patients.
Investigators hypothesize that Lugol solution might act through different mechanisms. It probably decreases both angiogenic stimuli and blood flow in Basedow's disease. Decreased angiogenesis and blood flow resulted in a significantly decreased number of visible vessels. Therefore, it is reasonable to think that increased vascular density could reflect increased angiogenic input to this disease. Lugol solution could also act directly to vessels wall, changing arteries and veins lumen.
These modifications could cause a reduction of intra-operative bleeding that could allow better visualization and preservation of the surrounding nerves, vasculature, and parathyroid glands and so better surgical and clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No pre-operative Lugol Solution preparation
Pre-operative Lugol preparation (10 drops per day orally three times a day for 7 days for an amount of 10,5 ml of Lugol solution that contains 1,68 gr of Iodine).
Other: Lugol -
Patients that undergo total thyroidectomy without Lugol solution pretreatment
Intra and post-operative blood loss (mL).
Blood loss volume (mL) as the amount of blood in the suction bottle and that absorbed by gauzes used during surgery was measured (volume calculated from the difference between dry gauzes weight and soaked gauzes weight). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Intra and post-operative bleeding (1st and 2nd day after surgery)
Post-operative laryngeal nerves palsy.
Evaluation of vocal cords disfunction. Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Laryngeal ultrasound on 1st and 2nd day and indirect laryngoscopy in case of dysphonia
Intra and post-operative thyrotoxicosis.
Heart rate \> 120 b/min detected during surgery or during post-operative hospital days. Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: During surgery and on 1st and 2nd day after surgery
Post-operative hypocalcemia (hypoparathyroidism, hungry bone syndrome).
serum calcium level less than 2,00 (8 mg/dl), with serum PTH inappropriately low (\<10 pg/mL). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Blood sample on 1st and 2nd day after surgery.
Change of ultrasound thyroid vascularization: blood flow velocity (v) variation (mm/sec).
US doppler of 4 thyroid arteries: blood flow velocity (v) (mm/sec) of the four main thyroid arteries, sampled near their entrance into the gland. Mean values for each artery is than calculated. Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Thyroid US doppler data: 7 days before surgery and the day before surgery (after 1 week).
Change of ultrasound thyroid vascularization: resistance index (RI) variation.
US doppler of 4 thyroid arteries: resistance index (RI) of the four main thyroid arteries, sampled near their entrance into the gland. It is the ratio between (peack systolic velocity-end diastolic velocity)/peack systolic velocity. Mean values for each artery is than calculated. Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Thyroid US doppler data: 7 days before surgery and the day before surgery (after 1 week).
Change of ultrasound thyroid vascularization: pulsatility index (PI) variation
US doppler of 4 thyroid arteries: pulstility index (PI) of the four main thyroid arteries, sampled near their entrance into the gland. It is the ratio between (peack systolic velocity-end diastolic velocity)/mean velocity. Mean values for each artery is than calculated. Evaluation of differences in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Thyroid US doppler data: 7 days before surgery and the day before surgery (after 1 week).
Change of US thyroid volume (mL).
Thyroid volume recorded through ultrasound (mL). It is also recorded directly after gland excision in the operating room (measuring the modification of the water volume inside a bowl after having dip the excised gland in the water bowl itself). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Thyroid US doppler data: 7 days before surgery and the day before surgery (after 1 week). Intra-operative thyroid volume detection (the day of surgery).
Change of thyroid tissue: immunohistochemical evaluation of thyroid tissue mean vessels density.
Thyroid vascularity evaluated through data recorded by hematoxylin and eosin sections and additional sections immunostained for CD-34 and CD-31. Section are scanned and mean vessels density is calculated by a specific softwear that recognizes CD31 and CD34 endothelial expression (specific colour expressed). The final count is then made by the softwear itself that through a machine learning method gives the section vessels total number and roe representative area mean vessels density. Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Post-operative pathological and immunoistochemical data recorded (in 30 days after surgery).
Change of thyroid vascularization stimuli: VEGF levels variation (pg/mL).
Thyroid vascularity evaluated through variation of VEGF plasmatic concentration (pg/mL) before and after Lugol solution assumption (when administrated). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Blood samples: 7 days before surgery and the day before surgery (after 1 week).
Change of thyroid function and biochemical data: FT3 and FT4 variation (pmol/L).
Serum FT3 and FT4 (pmol/L) levels variation before and after Lugol solution assumption (when administrated). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Blood samples: 7 days before surgery and the day before surgery (after 1 week).
Change of thyroid function and biochemical data: TSH variation (mIU/L).
Serum TSH (mIU/L) levels variation before and after Lugol solution assumption (when administrated). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Blood samples: 7 days before surgery and the day before surgery (after 1 week).
Change of thyroid function and biochemical data: Ab anti TG, Ab anti TPO, Ab anti TSH variation (U/L).
Serum Ab anti TG, Ab anti TPO, Ab anti TSH levels (U/L) variation before and after Lugol solution assumption (when administrated). Evaluation of differences (if any) in this outcome in the two groups of the study (Lugol assumption/no Lugol assumption).
Time frame: Blood samples: 7 days before surgery and the day before surgery (after 1 week).
Plan to share: No
Ran from Feb 2020 to primary completion in Jan 2023, 35 months.
Of 22 interventional studies with no phase under Graves Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 88. This study's 35 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.